The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
D000544:Alzheimer Disease / Q000188:drug therapy*; D053327:Apolipoprotein E4 / Q000032:analysis; D001057:Apolipoproteins E / Q000235:genetics; D054316:Biomarkers, Pharmacological / Q000032:analysis*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D015224:Dideoxynucleosides / Q000009:adverse effects; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D004342:Drug Hypersensitivity; D064420:Drug-Related Side Effects and Adverse Reactions; D055106:Genome-Wide Association Study; D005838:Genotype; D015235:HLA-B Antigens / Q000032:analysis*; D006801:Humans; D008954:Models, Biological; D010597:Pharmacogenetics / Q000191:economics / Q000379:methods*; D000077154:Rosiglitazone; D018401:Sample Size; D045162:Thiazolidinediones / Q000627:therapeutic use; D000099227:Abacavir
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D054316:Biomarkers, Pharmacological; D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D000077154:Rosiglitazone; D045162:Thiazolidinediones; D000099227:Abacavir; C484830:HLA-B*57:01 antigen